A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

[...] >=2 NSAIDs for the treatment of axSpA. Participants who are designated as biologic disease-modifying antirheumatic drug (BDMARD)(s) experienced; defined as below. Participants designated as bDMARD(s)-inadequate responder(bDMARD-IR) must have received not more than 2 approved bDMARD(s), that was/were administered in accordance with its/their labeling and was/werediscontinued inadequatelydue effectiveto: Non-response (primary or secondary) after thea minimum treatment of 12 weeks, and /or Intolerance (defined as having experienced an adverse reaction [e.g. an infusion/injection reaction, an inf [...] [...]

[...] ticipants aged 65 years or above on the date of signing the informed consent form (ICF), the investigator should carefully consider if participatio [...]

[...] 2), Have a history of inadequate response to >=2 NSAIDs at athe therapeuticmaximum dose rangeof NSAIDs used in axSpA for >=2 weeks each (a total duration of NSAID trial >=4 wee [...] as no change in prescription) for >4 weeks prior to Day 1. For participants aged 65 years or above on the date of signing the ICF, the investigator should carefully consider if participation is in the best interest of the participant. Key Exclusion Criteria: Prior exposure to a Janus kinase inh [...] clinically significant, as per judgment of the investigator, or history of a serious infection (requiring hospitalization or sy [...] [...]